Survival Outcomes of Patients with Pathologically Proven Positive Lymph Nodes at Time of Radical Cystectomy with or without Neoadjuvant Chemotherapy.

adjuvant bladder cancer chemotherapy neoadjuvant nodal disease pN1 radical cystectomy

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
23 Jun 2020
Historique:
received: 26 05 2020
revised: 11 06 2020
accepted: 22 06 2020
entrez: 27 6 2020
pubmed: 27 6 2020
medline: 27 6 2020
Statut: epublish

Résumé

To compare overall survival (OS) outcomes in pN1-3 disease at the time of radical cystectomy (RC) for muscle invasive bladder according to the neoadjuvant chemotherapy (NAC) status. This multicenter study included 450 consecutive patients undergoing RC for muscle-invasive urothelial bladder cancer with pN1-3 pM0 disease from 2010 to 2019. NAC consisted in platinum-based chemotherapy. The primary endpoint was the comparison between NAC and non-NAC in terms of death from any cause. OS was assessed using the Kaplan-Meier method and multivariate Cox proportional hazards regression was used to estimate adjusted hazard ratios. Median age was 69 years. Patients receiving NAC were younger ( Persistent nodal disease in RC specimens after NAC was associated with poor prognosis and lower OS rates compared with pN1-3 disease after upfront RC. In this sub-group of NAC patients, AC was independently associated with better OS.

Sections du résumé

BACKGROUND BACKGROUND
To compare overall survival (OS) outcomes in pN1-3 disease at the time of radical cystectomy (RC) for muscle invasive bladder according to the neoadjuvant chemotherapy (NAC) status.
MATERIALS AND METHODS METHODS
This multicenter study included 450 consecutive patients undergoing RC for muscle-invasive urothelial bladder cancer with pN1-3 pM0 disease from 2010 to 2019. NAC consisted in platinum-based chemotherapy. The primary endpoint was the comparison between NAC and non-NAC in terms of death from any cause. OS was assessed using the Kaplan-Meier method and multivariate Cox proportional hazards regression was used to estimate adjusted hazard ratios.
RESULTS RESULTS
Median age was 69 years. Patients receiving NAC were younger (
CONCLUSIONS CONCLUSIONS
Persistent nodal disease in RC specimens after NAC was associated with poor prognosis and lower OS rates compared with pN1-3 disease after upfront RC. In this sub-group of NAC patients, AC was independently associated with better OS.

Identifiants

pubmed: 32585894
pii: jcm9061962
doi: 10.3390/jcm9061962
pmc: PMC7356776
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

J Urol. 2007 Feb;177(2):437-43
pubmed: 17222605
Cancer. 2012 Jan 15;118(2):358-64
pubmed: 21717438
J Urol. 2018 Jun;199(6):1452-1458
pubmed: 29329894
BJU Int. 2014 Jul;114(1):67-74
pubmed: 24053889
JAMA Surg. 2018 Jan 17;153(1):e174591
pubmed: 29188298
J Clin Oncol. 2000 Sep;18(17):3068-77
pubmed: 11001674
Urology. 2009 Jan;73(1):147-52
pubmed: 18848348
J Clin Oncol. 2011 Jun 1;29(16):2171-7
pubmed: 21502557
Eur J Cancer. 2016 Dec;69:1-8
pubmed: 27814469
J Clin Oncol. 2018 Dec 1;36(34):3353-3360
pubmed: 30343614
Lancet Oncol. 2015 Jan;16(1):76-86
pubmed: 25498218
Clin Genitourin Cancer. 2015 Jun;13(3):e153-8
pubmed: 25510376
Eur Urol. 2014 Jul;66(1):42-54
pubmed: 24018020
J Clin Oncol. 1992 Jul;10(7):1066-73
pubmed: 1607913
J Urol. 2016 Jan;195(1):53-9
pubmed: 26205531
N Engl J Med. 2003 Aug 28;349(9):859-66
pubmed: 12944571
Eur Urol. 2005 Aug;48(2):202-5; discussion 205-6
pubmed: 15939524

Auteurs

Guillaume Ploussard (G)

Department of Urology, La Croix du Sud Hospital, 31130 Quint Fonsegrives, France.

Benjamin Pradere (B)

Department of Urology, Bretonneau Hospital, 37000 Tours, France.
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.

Jean-Baptiste Beauval (JB)

Department of Urology, La Croix du Sud Hospital, 31130 Quint Fonsegrives, France.

Christine Chevreau (C)

Department of Oncology, IUCT-O, 31000 Toulouse, France.

Christophe Almeras (C)

Department of Urology, La Croix du Sud Hospital, 31130 Quint Fonsegrives, France.

Etienne Suc (E)

Department of Oncology, La Croix du Sud Hospital, 31130 Quint Fonsegrives, France.

Jean-Romain Gautier (JR)

Department of Urology, La Croix du Sud Hospital, 31130 Quint Fonsegrives, France.

Anne-Pascale Laurenty (AP)

Department of Oncology, La Croix du Sud Hospital, 31130 Quint Fonsegrives, France.

Mathieu Roumiguié (M)

Department of Urology, CHU-IUC, 31000 Toulouse, France.

Guillaume Loison (G)

Department of Urology, La Croix du Sud Hospital, 31130 Quint Fonsegrives, France.

Christophe Tollon (C)

Department of Urology, La Croix du Sud Hospital, 31130 Quint Fonsegrives, France.

Loïc Mourey (L)

Department of Oncology, IUCT-O, 31000 Toulouse, France.

Ambroise Salin (A)

Department of Urology, La Croix du Sud Hospital, 31130 Quint Fonsegrives, France.

Evanguelos Xylinas (E)

Department of Urology, Bichat-Claude Bernard Hospital, Assistance Publique-Hopitaux de Paris, Paris University, 75018 Paris, France.

Damien Pouessel (D)

Department of Oncology, IUCT-O, 31000 Toulouse, France.

Classifications MeSH